{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-238059","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-05-26T12:56:06+00:00","discovered_at":"2026-05-26T13:00:00.421774+00:00","generated_at":"2026-05-26T13:00:18.417122+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"Corbus reports CRB-701 42.9% cORR in 2L OPSCC at 3.6 mg/kg; registrational study planned summer 2026","bullets":["cORR 42.9% (9/21) in 2L OPSCC at 3.6 mg/kg; median DOR 6.3 mo, PFS 5.6 mo.","cORR 34.4% (11/32) in 2L cervical cancer at 3.6 mg/kg; 2 complete responses, DOR 8.0 mo.","Safety: treatment discontinuations 2.8%; no Grade 5 events; ocular AEs manageable.","FDA alignment on registrational trials: TEMPO-1 (OPSCC, n=250) to start summer 2026.","85.4% of OPSCC patients HPV+; 8 of 9 responders in OPSCC were HPV+."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-238059","json":"https://secwatch.observer/filing/0001193125-26-238059.json","markdown":"https://secwatch.observer/filing/0001193125-26-238059.md","text":"https://secwatch.observer/filing/0001193125-26-238059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/0001193125-26-238059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/crbp-20260526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T13:00:18.417122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}